DiscGenics announces the publication in The Spine Journal of Preclinical Data for Disc Degeneration

DiscGenics, Inc., a biopharmaceutical business in the clinical phase, concentrated on creating regenerative cell-based therapies that relieve pain and restore function in patients with spine degenerative diseases, announced today the online publication of a study in The Spine Journal[1] summarizing…

ContraVir Pharmaceuticals sets the CRV431 Development’s stage

ContraVir Pharmaceuticals, Inc., a biopharmaceutical organization concentrated on the improvement of restorative medications for the treatment of liver illness emerging from non-alcoholic steatohepatitis (“NASH”) and unending viral contamination, today reported discoveries from a preclinical report where CRV431, a novel cyclophilin…

Onychomycosis and Identified Major Targets using CAGR

Abbott Laboratories Ltd. (US), Pfizer Inc. (US), Valeant Pharmaceuticals (Canada), GlaxoSmithKline Plc. (UK), Galderma (Switzerland), Bristol Meyer Squibb organization (US), Cutera Inc. (US), Janssen Biotech (US), Sciton Inc (US), Novartis AG (Switzerland), Taro Pharmaceutical Industries Ltd. (US), Seren Pharmaceuticals Pvt.…